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Abstract 
Background 
There is an increased risk of developing T2DM in women with polycystic ovary 
syndrome (PCOS) and there is evidence that statins improve metabolic parameters in 
these patients. However, there is some data to show that statins increase the risk of 
incipient diabetes. 
Material and Methods 
We have previously shown that 12-weeks of atorvastatin improves insulin resistance 
when measured using HOMA-IR.  This post hoc-analysis was designed to look at the 
effect of atorvastatin on pancreatic β cell function using HOMA-β in the same study.  In 
this randomised, double blind placebo controlled study, 40 medication naïve patients with 
PCOS were randomized to either atorvastatin 20 mg daily or placebo for 3 months.  A 3-
month extension study for both groups of patients was undertaken with metformin 1500 
mg daily after completing initial 3 months of atorvastatin or placebo.   
Results 
There was a significant reduction in HOMA-β (240±3.2vs.177±2.3; pvalue<0.01) after 12 
weeks of atorvastatin treatment which was maintained by metformin in the subsequent 12 
weeks.  There were no changes in HOMA-β after the placebo or after subsequent 
metformin treatment.   
There was no linear correlation between reduction in HOMA-β with improvement of free 
androgen index (FAI) (r2=0.02;p=0.72), testosterone (r2=0.13;p=0.49), SHBG 
(r2=0.22;p=0.48), hsCRP (r2=0.19;p=0.64), triglycerides (r2=0.09;p=0.12), total 
cholesterol (r2=0.11;p=0.32) or LDL-C (r2=0.19;p=0.38). 
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Conclusion 
Treatment with atorvastatin for 12 weeks in women with PCOS significantly reduced 
HOMA-β.  This could be potentially due to fall in βcell requirement with improvement 
of insulin resistance rather than a reduction of βcell function. 
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Background 
Statin (HMG-CoA reductase) treatment is effective in the primary and secondary 
prevention of cardiovascular disease (CVD) events 1, 2 and is generally safe and well 
tolerated 2. In the West of Scotland Coronary Study (WOSCOPS) pravastatin treatment 
decreased the risk of type 2 diabetes (T2DM) by 30%3. Emerging evidence, however, 
suggests that treatment with other statins slightly increase the risk of T2DM 4 5. In pooled 
data sets statin therapy was associated with a 9% increased risk of diabetes6 and this 
effect was age and dose dependent7. Population-based studies have also reported a 10–
22% increased risk of diabetes with statins 8. However, there is also increasing evidence 
that reduction in insulin resistance especially with weight loss in patients with T2DM will 
result in normalisation of pancreatic β-cell requirement and even reversal of T2DM 9. 
Statins have shown to improve certain features of polycystic ovary syndrome (PCOS) 
such as hyperandrogenemia 10-13. PCOS is one of the most common endocrine disorders 
that affects 6-20% of reproductive-aged women 14-16 and is at an increased risk of T2DM 
17, 18
. Seventy five to 90% of PCOS patients demonstrate insulin resistance (IR) above 
and beyond that predicted by body mass, race, or age 19, 20 resulting in compensatory 
hyperinsulinaemia 21 and an increased risk for (T2DM) 22 and cardiovascular disease 23.  
However, the effect of statins in improving insulin resistance is variable 10-13, 24.  Insulin 
resistance in most of these studies used HOMA-IR, which is a derivative use to measure 
insulin resistance from insulin and glucose. We have previously shown that 12 weeks of 
atorvastatin improves insulin resistance when measured using HOMA-IR 10, 11.  This 
post-hoc analysis was designed to look at the effect of atorvastatin in insulin secretion 
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using HOMA-β in the same study and its correlation with other hormonal and metabolic 
parameters.   
Materials and Methods 
A randomized double blind placebo controlled study was undertaken using atorvastatin 
20mg daily 11.  An extension arm followed this where immediately after stopping the 
study medication, 37 patients (19 patients from the atorvastatin group and 18 patients 
from the placebo group) who completed the study were given metformin 500mg three 
times daily for 3 months10.  Clinical and biochemical assessments were performed at 
baseline, at the end of the 3-month period and at the end of 6 months after the extension 
phase.  
The diagnosis of PCOS was based on all three diagnostic criteria of the Rotterdam 
consensus, namely clinical and biochemical evidence of hyperandrogenemia (Ferriman-
Gallwey score >8; free androgen index >8 respectively), oligomenorrhoea or amenorrhea 
and polycystic ovaries on transvaginal ultrasound 25.  Subjects had no concurrent illness, 
were not on any medication for the preceding 6 months and were not planning to 
conceive. All patients gave written informed consent.  The study was approved by the 
Hull and East Riding Local Research Ethics committee.   
Study bloods and measurement were done after an overnight fast.  Compliance was 
monitored by counting returned medication. Fasting venous blood was collected into 
serum gel and fluoride oxalate tubes. Samples were separated by centrifugation at 2000 g 
for 15 min at 4oC, and the aliquots stored at –20oC.  Analytical methods have been 
described previously11. The insulin resistance was calculated using the homeostasis 
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model assessment (HOMA) method (HOMA-IR= (insulin x glucose)/22.5). Pancreatic 
beta cell function (HOMA-β) was calculated using (HOMA-β = (20 x insulin)/glucose-
3.5).  Data are reported as mean ± SEM. 
Statistical analysis 
The sample size calculation for the original study was based on the known effects of 
atorvastatin on CRP in patients with impaired fasting glucose with the assumption that a 
similar effect occurs in those with PCOS 11, 26. For 90% power, significance level of 5% 
and adjusting for a possible 20% dropout rate, 20 subjects were enrolled in each group. 
   
Comparisons between both the groups from baseline were carried out using the paired t 
test for biochemical data and clinical observations. The Wilcoxon signed rank test was 
applied to biochemical data that violated the assumptions of normality when tested using 
the Kolmogorov-Smirnov test. Between-group comparison of percent changes was 
performed using independent samples t test. Intention to treat analysis was done.  For all 
analysis, a two-tailed P ≤0.05 was considered to indicate statistical significance. 
Statistical analysis was performed using SPSS for Windows NT, version 14.0 (SPSS Inc., 
Chicago, IL).   
Results:   
Thirty seven patients completed the study.  Two patients from the placebo group and one 
patient from atorvastatin group dropped out of the study due to non-compliance.  
The mean age group of patients was 27.7 ± 1.4 years (atorvastatin 26.6 ± 1.2 vs. placebo 
28.8 ± 1.8).   The BMI were comparable in both atorvastatin and placebo group (33.20 ± 
1.4 vs. 33.92 ± 1.4 kg/m2).   
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There was a significant reduction in serum insulin levels and HOMA-IR in patients 
taking atorvastatin whilst there was significant increase in both these parameters in 
patients randomised to placebo.  In the extension phase there were significant reduction 
in insulin and the HOMA-IR with metformin in the atorvastatin pre-treated group 
whereas, no significant changes in any of these parameters with metformin in the placebo 
pre-treatment group.   
However, there was a significant reduction in HOMA-β (240. ± 3.2 vs. 177 ± 2.3; p 
value<0.01) after 12 weeks of atorvastatin treatment compared to placebo, which was 
maintained by metformin in the subsequent 12 weeks (177 ± 2.3 vs. 185 ± 3.3; p value 
0.42).  There were no changes in HOMA-β after the placebo (Table 1).  
There was no linear correlation between reduction in HOMA-β with improvement of FAI 
(r2=0.02; p=0.72), testosterone (r2=0.13; p=0.49), SHBG (r2=0.22; p=0.48), hsCRP 
(r2=0.19; p=0.64), triglycerides (r2=0.09; p=0.12), total cholesterol (r2=0.11; p=0.32) or 
LDL-C (r2=0.19; p=0.38). 
Discussion 
In women with PCOS 12 weeks treatment with atorvastatin 20mg resulted in a significant 
reduction in pancreatic beta cell requirement as assessed by HOMA-β.  This was 
independent of the improvement seen in the inflammatory markers, insulin resistance, 
lipids and hyperandrogenemia. 
There was 26% reduction in pancreatic beta cell requirement as assessed by HOMA-β 
with atorvastatin treatment in this study compared to 20% reduction in insulin resistance 
as measured by HOMA-IR.  It has been shown that in patients with T2DM, severe calorie 
restriction reverse T2DM with reduction of insulin resistance and normalisation of 
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pancreatic β-cell requirement 9.  After 12 weeks of atorvastatin in this study there was a 
significant improvement in insulin resistance as measured by HOMA-IR.  This reduction 
in insulin resistance would have resulted in fall in the β-cell requirements.   Another 
possibility is that the statin could have a direct deleterious effect on β-cells by multiple 
mechanisms. Statins have been shown to inhibit this glucose-induced calcium signaling-
dependent insulin secretion 27. In addition, statins suppress the synthesis of ubiquinone 
(CoQ10), an essential factor in the mitochondrial electron-transfer system, resulting in 
inhibition of insulin secretion due to reduced production of ATP 28.  However, it is 
unlikely that the β-cell function fell more than expected by the reduction in insulin 
resistance since there was no significant hyperglycaemia after 12 weeks of atorvastatin 
therapy as measured by fasting glucose. This reduction in HOMA- β was maintained after 
subsequent metformin treatment.  However, there were no significant changes in HOMA- 
β after placebo or subsequent metformin treatment.     
This study used atorvastatin that is a lipid-soluble statin.  There could be a 
differential effect of statins depending on lipid solubility rather than a class effect.  
Lipophilic statins such as simvastatin and atorvastatin are possibly absorbed by 
extra-hepatic cells; these statins can deregulate cholesterol metabolism, thus 
attenuating β-cell function 29.  However, in the West of Scotland Coronary Study 
(WOSCOPS) treatment with pravastatin which is a water-soluble statin decreased the risk 
of diabetes by 30%3. There are currently no studies reported looking into the effect of 
non-lipophilic statins in women with PCOS.   
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There was no significant correlation with reduction of lipids, inflammatory markers, and 
hormonal parameters with reduction in HOMA-β.  This shows that the effect of 
atorvastatin on HOMA-β is independent of its lipid lowering effect.   
The limitation of the study includes the fact that this is a post-hoc analysis, however, 
all the biochemical analysis was done immediately after the study so that is should 
not affect the validity of analysis. For measurement of pancreatic beta cell function, 
hyperglycaemic insulin clamp studies or intravenous glucose tolerance test ideal, 
however in this study we calculated HOMA-β using fasting glucose and insulin 
measurements. HOMA-β correlates well with other methods of assessment of 
pancreatic beta cell function over a wide range of glucose tolerance status (r=0.69 
vs. hyperglycemic clamp; r=0.62-0.90 for normal glucose tolerance; r=0.73-0.88 for 
impaired glucose tolerance; r=0.69-0.90 for diabetes)30, 31. However, more elaborate 
studies are needed to ascertain the effect of atorvastatin on beta cell function 
including insulin clamp studies. 
In conclusion, treatment with atorvastatin for 12 weeks in women with PCOS 
significantly reduced HOMA-β.  This could be potentially due to fall in β cell 
requirement with improvement of insulin resistance rather than suppression of β 
cell function, since there were no significant hyperglycaemia or hyperinsulinemia 
after atorvastatin therapy. 
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Table 1. Comparison of anthropometric and hormonal parameters at baseline, 12 weeks of atorvastatin or placebo followed by 12 weeks of metformin. 
 
 
   
 
Atorvastatin group – Atorvastatin for 12 weeks followed by Metformin for 12 weeks. 
Placebo group – Placebo for 12 weeks followed by Metformin for 12 weeks. 
V1 – Baseline; V2 – 12 weeks from baseline on either atorvastatin or placebo; V3 - 24 weeks from baseline (12 weeks from visit 2 on 
Metformin 1.5g daily) 
p* - p value for percentage difference between both group using unpaired t test 
*pvalue < 0.01 
Data are presented as mean ± SEM. All serum results are obtained from fasting variables. 
All variables were normally distributed 
To convert values for testosterone to nanograms per deciliter, divide by 0.03467.  
Parameter Atorvastatin group Placebo group 
 Baseline 
(V1) 
12 weeks (V2) 
(Atorvastatin 
20mg daily) 
24 weeks 
(V3) 
(Metformin 
1.5gm daily) 
V1/V2 
(pvalue
) 
%change 
V1-V2 
V1/V3 
(p 
value) 
Baseline 
(V1) 
12 weeks 
(V2) 
(Placebo) 
24 weeks 
(V3) 
(Metformin 
1.5gm daily) 
V1/V2 
(p 
value) 
%change 
V1-V2 
V1/V3 
(p 
value) 
Weight (kg) 91.29 ± 3.4 91.20 ± 3.4 90.3 ± 3.1 
 
0.42 0.1 ± 0.1 0.08 93.12 ± 4.8 93.05 ± 
4.7 
92.6 ± 3.2 0.67 0.03 ± 0.02 0.12 
Testosterone 
(nmol/L) 
4.1 ± 0.2 2.9 ± 0.1 2.7 ± 0.1 <0.01 -24.6 ± 2.6 <0.01 4.4 ± 0.2 4.3 ± 0.2 4.2 ± 0.8 0.73 -0.1 ± 1.5 0.18 
SHBG (nmol/L) 31.1 ± 1.0 35.3 ± 1.2 36.6 ± 1.7 <0.01 13.7 ± 2.4 <0.01 31.9 ± 0.9 32.9 ± 0.9 32.2 ± 0.8 0.14 3.6 ± 2.0 0.8 
FAI 13.4 ± 0.6 8.7 ± 0.4 7.6 ± 0.9 <0.01 -32.7 ± 2.6 <0.01 13.9 ± 0.6 13.3 ± 0.5 13.1 ± 0.9 0.07 -- 3.1 ± 2.0 0.14 
Glucose 
(mmol/L) 
4.8 ± 0.1 4.9 ± 0.1 4.6 ± 0.1 0.52 1.0 ± 2.0 0.47 4.7 ± 0.5 4.8 ± 0.1 4.6 ± 0.4 0.32 2.0 ± 1.0 0.33 
Insulin 
(µIU/mL) 
15.6 ± 1.8 12.4 ± 1.7 10.2 ± 1.8 <0.01 -21.4 ± 4.0 <0.01 14.4 ± 2.0 17.6 ± 2.4 16.4 ± 1.8 0.04 34.2 ± 19.7 0.32 
HOMA-IR 3.3 ± 0.4 2.7 ± 0.4 2.0 ± 0.8 <0.01 -19.8 ± 5.2 0.04 3.0 ± 0.4 3.8 ± 0.5 3.4 ± 0.3 0.04 37.2 ± 20.4 0.36 
HOMA-β 240. ± 3.2 177 ± 2.3 185 ± 3.3 <0.01 -26.3  ± 1.1 0.07 240 ± 4.2 270 ± 8.2 298 ± 3.6 0.10 12.5 ± 1.0 0.08 
TC (mmol/L) 4.6 ± 0.2 3.4 ± 0.2 3.9 ± 0.5 <0.01 - 26.4 ± 3.0 0.82 4.5 ± 0.2 4.6 ± 0.2 4.5 ± 0.3 0.13 3.1 ± 1.1 0.82 
LDL-C 
(mmol/L) 
2.9 ± 0.2 1.8 ± 0.2 2.8 ± 0.4 <0.01 - 36.6 ± 5.0 0.04 2.7 ± 0.2 2.7 ± 0.1 2.9 ± 0.3 0.77 3.1 ± 0.9 0.70 
HDL-C 
(mmol/L) 
1.07 ± 0.1 1.08 ± 0.1 1.07 ± 0.2 0.17 - 4.0 ± 3.9 0.20 1.1 ± 0.08 1.1 ± 0.09 1.1 ± 0.1 0.47 3.0 ± 3.2 0.70 
TG (mmol/L) 1.34 ± 0.08 1.08 ± 0.1 1.01 ± 0.1 <0.01 - 20.9 ± 3.8 0.05 1.39 ± 0.24 1.69 ± 
0.27 
1.34 ± 0.1 0.19 36.8 ± 21.0 0.82 
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To convert values for SHBG to micrograms per deciliter, divide by 34.7.  
To convert values for glucose to milligrams per deciliter, divide by 0.056.  
To convert values for insulin to picomoles per liter, multiply by 6.  
To convert values for cholesterol to milligrams per deciliter, divide by 0.0259. 
 To convert values for triglycerides to milligrams per deciliter, divide by 0.0113.  
TC - Total cholesterol; LDL-C - LDL-cholesterol; HDL-C - HDL cholesterol; TG-Triglycerides; FAI – Free Androgen Index 
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